Cyclophosphamide Toxicity
- 1 November 1991
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 42 (5), 781-795
- https://doi.org/10.2165/00003495-199142050-00005
Abstract
Cyclophosphamide, an orally active alkylating agent, is widely used to treat a variety of malignant and nonmalignant disorders. Although it has some tumour selectivity, it also possesses a wide spectrum of toxicities. The requirement of metabolic activation before cyclophosphamide exerts either its therapeutic or toxic effects is well established, but has not led to effective countermeasures. Clinically, damage to the bladder (haemorrhagic cystitis), immunosuppression (when not desired) and alopecia are the most significant toxicities associated with cyclophosphamide. Cardiotoxicity is also a possibility when very high doses are given. Preventing these toxicities has focused on modifications of the treatment regimens and, in the case of haemorrhagic cystitis, the administration of a drug which is excreted in the urine where it inactivates the bladder-toxic species. As treatment regimens for cancer become more effective in prolonging a patient’s life, and as cyclophosphamide receives increasing use for nonmalignant disorders, the potential for cyclophosphamide-induced cancers, particularly in the bladder, must be recognised. Although the toxicities associated with cyclophosphamide are serious, this agent remains a highly effective drug in many situations. Research on the pathways which play an important role in activating this drug may improve our ability to target particular diseases and decrease unwanted side effects.Keywords
This publication has 69 references indexed in Scilit:
- Metabolism and pulmonary toxicity of cyclophosphamidePharmacology & Therapeutics, 1990
- Cancer chemotherapy after solid organ transplantationCancer, 1990
- Cyclophosphamide-induced hemorrhagic cystitis: A review of 100 patientsCancer, 1988
- Increased Pulmonary Collagen Synthesis in Mice Treated with CyclophosphamideDrug and Chemical Toxicology, 1985
- Biochemical indices of cyclophosphamide-induced lung toxicityToxicology and Applied Pharmacology, 1984
- Effect of Treatment on the Evolution of Renal Abnormalities in Lupus NephritisNew England Journal of Medicine, 1984
- Cyclophosphamide cystitis and bladder cancer. A hypothesisEuropean Journal of Cancer (1965), 1979
- Scalp Tourniquet in the Prevention of Chemotherapy-Induced AlopeciaNew England Journal of Medicine, 1978
- Cyclophosphamide therapy and interstitial pulmonary fibrosisCancer, 1976
- Cyclophosphamide-induced hemorrhagic cystitis in children with leukemiaCancer, 1975